Immuno-engineering @AdaptinBio @prtbtcatduke MD, PhD @QMULBartsTheLon @DukeUBME 🇬🇧 in 🇺🇸
Joined January 2011
- Tweets65
- Following727
- Followers160
- Likes429
Kirit Singh retweeted
News from @DukeMedSchool features APTN-101, Adaptin Bio’s BRiTE immunotherapy being studied in a Phase I glioblastoma trial. The therapy is designed to cross the blood-brain barrier and direct T cells to EGFRvIII-expressing tumor cells.
Read: bit.ly/4j4Xesn $APTN
Excited to get this trial studying EGFRvIII-BRiTE off the ground in partnership with @AdaptinBio! Duke-developed immunotherapy for brain tumors heads to clinical trial medschool.duke.edu/news/duke…
Kirit Singh retweeted
1/ Today, we’re introducing Geodesic Intelligence, and launching NovaDDE and NovaAtom-Lite-Preview.
Geodesic is building an AI-native platform for protein therapeutics, building AGI for drug discovery to find the shortest path from biology to medicines.
geodesiclab.com
Delighted that our surgical window of opportunity trial re-purposing the PCSK9 inhibitor Evolocumab in glioma (PesKe) is out in @SciReports.
Grateful for all the hard work by the team led by @MKhasraw with support across @prtbtcatduke @Dukeneurosurg 🧵⬇️
nature.com/articles/s41598-0…
11/ We are hugely grateful for the support of generous donors like the Knox Martin Foundation @BeckyMartinCom and the Langford-Cregger Foundation. Complex tissue-based trials re-purposing already commercialized drugs like PesKE would not be possible without these amazing groups.
Kirit Singh retweeted
We are pleased to have Dr. @KiritSingh as our Chief Scientific Consultant!
Dr. Singh is a Duke University scientist engaged in research supporting Adaptin Bio's APTN-101 program in glioblastoma. 🧠 Check out his bio: bit.ly/4luwfVl
#GBM #Science
Kirit Singh retweeted
In glioma, T cell immunotherapies are limited by the quantity of available T cells.
@KiritSingh @PeterFecci @MKhasraw & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7.
Full report jci.org/articles/view/181471
Kirit Singh retweeted
🧠✨ We’re thrilled to welcome these 3 great minds: Grace Futch, MD (@B_Grace_Futch) & Aden Mendoza, MD, of @DukeMedSchool; & Molly Monsour, MD (@mollymonsour_) of @USouthFlorda. We can’t wait to see them scrub in, step up, and shape the future of neurosurgery. #Match2025
Kirit Singh retweeted
Glioma Surgeons: Think the tumor cells in your 5-ALA-treated patients are fluorescing? Think again!
@TumorSection @nyulangone @Perlmutter_CC nature.com/articles/s41551-0…
Kirit Singh retweeted
Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor medrxiv.org/content/10.1101/… @KiritSingh
